IOF and IFCC review describes the current status of assays for reference bone turnover markers
Bone turnover markers (BTMs) in blood and urine are useful tools in monitoring osteoporosis treatment effects and may be useful for improving patient adherence.
In 2011, a Joint Committee on Bone Metabolism of the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) designated Procollagen type I N-propeptide (PINP) and the C-terminal telopeptide of type I collagen (β-CTX) in blood as reference bone turnover markers for bone formation and bone resorption, respectively, in osteoporosis. However, the effective clinical implementation of these recommendations requires the standardization/harmonization of commercial assays.
E-Mail
Bone turnover markers (BTMs) in blood and urine are useful tools in monitoring osteoporosis treatment effects and may be useful for improving patient adherence.
In 2011, a Joint Committee on Bone Metabolism of the International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) designated Procollagen type I N-propeptide (PINP) and the C-terminal telopeptide of type I collagen (β-CTX) in blood as reference bone turnover markers for bone formation and bone resorption, respectively, in osteoporosis. However, the effective clinical implementation of these recommendations requires the standardization/harmonization of commercial assays [1].
As well as a review of the structures of PINP and β-CTX molecules, the authors provide a succinct, referenced summary of current commercial assays, their descriptions, and performance characteristics. Key characteristics and performance specifications of the four commercial